US · DRUG
Bright Minds Biosciences Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, BC V6E 4N7
- Website
- brightmindsbio.com
Price · as of 2025-09-30
$86.96
Market cap 650.57M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $19.10 | ||||
| 2022 | $5.20 | ||||
| 2023 | $1.56 | ||||
| 2024 | $38.51 | ||||
| 2025 | $80.50 |
AI valuation
Our deep-learning model estimates Bright Minds Biosciences Inc.'s (DRUG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $86.96
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DRUG | Bright Minds Biosciences … | $86.96 | 650.57M | — | — | — | — | -63.26 | 9.43 | — | -49.84 | -36.39 | 9.43 | 0.00% | — | — | -27.93% | 3472.77% | -27.02% | 0.00 | — | 36.10 | 35.68 | 5.97 | 17385.00% | — | 36977.00% | -1.12% | -3.72 | 2165.66% | 0.00% | 0.00% | 9.98% | -49.57 | -79.48 | — | 195.16 |
| ALT | Altimmune, Inc. | $4.31 | 380.39M | +632% | -46% | — | +2,482% | -4.16 | 3.20 | 19774.45 | -2.80 | — | 3.20 | 100.00% | -515860.00% | -475295.00% | -59.86% | 2117.00% | -54.33% | 0.01 | -11463.56 | 13.11 | 12.90 | 0.37 | -1928.00% | -9531.00% | 526.00% | -20.19% | -7.63 | 1638.41% | 0.00% | 0.00% | 0.00% | -2.57 | -3.32 | 13263.95 | 8.03 |
| ANNX | Annexon, Inc. | $5.60 | 669.73M | — | — | — | — | -2.74 | 1.29 | — | -0.71 | — | 1.29 | 0.00% | — | — | -50.84% | -955.34% | -42.67% | 0.10 | — | 10.37 | 10.23 | 0.15 | -4294.00% | — | -273.00% | -31.12% | -3.87 | -731.80% | 0.00% | 0.00% | 0.00% | -0.62 | -0.82 | — | 0.68 |
| AURA | Aura Biosciences, Inc. | $5.89 | 374.03M | — | — | — | — | -4.23 | 2.42 | — | -2.48 | — | 2.42 | 0.00% | — | — | -46.01% | -494.17% | -39.73% | 0.12 | — | 10.77 | 10.13 | 0.14 | -933.00% | — | 2556.00% | -22.06% | -5.35 | -416.75% | 0.00% | 0.00% | 0.00% | -2.45 | -2.90 | — | 3.57 |
| DMAC | DiaMedica Therapeutics In… | $7.95 | 414.02M | — | — | — | — | -9.54 | 5.73 | — | -7.11 | — | 5.73 | 0.00% | — | — | -53.27% | 1178.75% | -48.64% | 0.01 | — | 8.28 | 8.23 | 0.10 | 0.00% | — | 1786.00% | -9.48% | -4.10 | 976.41% | 0.00% | 0.00% | 0.00% | -7.10 | -8.57 | — | 19.75 |
| DSGN | Design Therapeutics, Inc. | $10.44 | 594.7M | — | — | — | — | -5.61 | 1.15 | — | -0.72 | — | 1.15 | 0.00% | — | — | -19.08% | 5921.50% | -18.31% | 0.01 | — | 29.31 | 29.16 | 0.41 | -2605.00% | — | -2613.00% | -15.60% | -5.09 | 4123.87% | 0.00% | 0.00% | 0.75% | -0.57 | -0.81 | — | 15.77 |
| ENGN | enGene Holdings Inc. | $10.11 | 517.58M | — | — | — | — | -3.84 | 2.69 | — | -2.53 | -6.75 | 2.69 | 0.00% | — | — | -53.28% | -379.44% | -44.05% | 0.19 | -41.14 | 6.30 | 6.13 | 0.16 | 5685.00% | — | 10470.00% | -22.37% | -3.10 | -310.30% | 0.00% | 0.00% | 0.00% | -2.34 | -2.86 | — | 1.76 |
| GALT | Galectin Therapeutics Inc… | $2.98 | 192.13M | — | — | — | — | -2.15 | -0.98 | — | -4.63 | -79.38 | -0.98 | 0.00% | — | — | 57.62% | 325.92% | -205.92% | -1.03 | -7.66 | 0.49 | 0.43 | -2.20 | 270.00% | — | 2670.00% | -41.38% | -1.18 | 320.80% | 0.09% | -0.20% | 0.09% | -4.53 | -4.60 | — | -40.88 |
| KRRO | Korro Bio, Inc. | $12.13 | 114.23M | — | -2% | — | — | -2.38 | 1.24 | 87.71 | -1.33 | — | 1.24 | 100.00% | -4047.12% | -3680.36% | -50.61% | -158.39% | -37.32% | 0.28 | — | 8.79 | 8.54 | 0.12 | -8235.00% | — | 380.00% | -39.15% | -4.02 | -134.38% | 0.00% | 0.00% | 0.00% | -1.28 | -1.51 | 51.90 | -0.55 |
| LBRX | LB Pharmaceuticals Inc Co… | $24.01 | 607.43M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 97.81% | 65.95% | -159.37% | -0.04 | — | 3.56 | 3.45 | 0.31 | 90734.00% | — | 34410.00% | — | -6.54 | 54.75% | — | 0.00% | — | — | — | — | — |
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
- CEO
- Ian McDonald
- Employees
- 0
- Beta
- -0.49
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $86.96) − 1 = — (DCF, example).